Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
08/09/2023 | Paratek Pharmaceuticals, Inc. | PRTK | Sale | Common Stock | 31.2k | $2.20 | $68.8k | | 08/08/2023 |
08/08/2023 | Paratek Pharmaceuticals, Inc. | PRTK | Grant | Common Stock | 156.2k | $0.00 | $0 | | 08/08/2023 |
12/13/2022 | Paratek Pharmaceuticals, Inc. | PRTK | Sale | Common Stock | 31.9k | $1.96 | $62.5k | | 12/12/2022 |
12/12/2022 | Paratek Pharmaceuticals, Inc. | PRTK | Sale | Common Stock | 19.5k | $1.98 | $38.6k | | 12/12/2022 |
11/22/2022 | Frazier Lifesciences Acquisition Corp | | Exercise | Class B Ordinary Shares | 30k | $0.00 | $0 | | 11/22/2022 |
08/09/2022 | Paratek Pharmaceuticals, Inc. | PRTK | Sale | Common Stock | 28.6k | $2.66 | $76.2k | | 08/08/2022 |
08/08/2022 | Paratek Pharmaceuticals, Inc. | PRTK | Grant | Common Stock | 143.2k | $0.00 | $0 | | 08/08/2022 |
03/15/2022 | Paratek Pharmaceuticals, Inc. | PRTK | Grant | Common Stock | 202.5k | $0.00 | $0 | | 03/15/2022 |
12/15/2021 | Paratek Pharmaceuticals, Inc. | PRTK | Sale | Common Stock | 17.8k | $4.27 | $76.1k | | 12/13/2021 |
12/14/2021 | Paratek Pharmaceuticals, Inc. | PRTK | Sale | Common Stock | 8.6k | $4.37 | $37.7k | | 12/13/2021 |
12/13/2021 | Paratek Pharmaceuticals, Inc. | PRTK | Sale | Common Stock | 5.1k | $4.42 | $22.4k | | 12/13/2021 |
11/24/2021 | Adamas Pharmaceuticals Inc | ADMS | Disposition | Stock Option (Right to Buy) | 10k | $4.80 | $48k | | 11/24/2021 |
11/24/2021 | Adamas Pharmaceuticals Inc | ADMS | Disposition | Stock Option (Right to Buy) | 10k | $2.70 | $27k | | 11/24/2021 |
11/24/2021 | Adamas Pharmaceuticals Inc | ADMS | Disposition | Stock Option (Right to Buy) | 10k | $5.21 | $52.1k | | 11/24/2021 |
11/24/2021 | Adamas Pharmaceuticals Inc | ADMS | Other | Common Stock | 10k | $0.00 | $0 | | 11/24/2021 |
06/04/2021 | Paratek Pharmaceuticals, Inc. | PRTK | Sale | Common Stock | 34.4k | $9.70 | $333.3k | | 05/27/2021 |
06/02/2021 | Adamas Pharmaceuticals Inc | ADMS | Grant | Stock Option (Right to Buy) | 10k | $5.21 | $52.1k | | 06/02/2021 |
06/02/2021 | Adamas Pharmaceuticals Inc | ADMS | Grant | Common Stock | 5k | $0.00 | $0 | | 06/02/2021 |
05/27/2021 | Paratek Pharmaceuticals, Inc. | PRTK | Grant | Common Stock | 85.9k | $0.00 | $0 | | 05/27/2021 |
12/14/2020 | Paratek Pharmaceuticals, Inc. | PRTK | Sale | Common Stock | 26.1k | $6.71 | $174.9k | | 12/11/2020 |
12/11/2020 | Paratek Pharmaceuticals, Inc. | PRTK | Sale | Common Stock | 18.3k | $6.95 | $127.4k | | 12/11/2020 |
11/13/2020 | Paratek Pharmaceuticals, Inc. | PRTK | Sale | Common Stock | 26.2k | $5.93 | $155.7k | | 11/12/2020 |
11/12/2020 | Paratek Pharmaceuticals, Inc. | PRTK | Grant | Common Stock | 75k | $0.00 | $0 | | 11/12/2020 |
06/03/2020 | Adamas Pharmaceuticals Inc | ADMS | Grant | Common Stock | 5k | $0.00 | $0 | | 06/03/2020 |
06/03/2020 | Adamas Pharmaceuticals Inc | ADMS | Grant | Stock Option (Right to Buy) | 10k | $2.70 | $27k | | 06/03/2020 |
05/12/2020 | Paratek Pharmaceuticals, Inc. | PRTK | Sale | Common Stock | 12.2k | $4.68 | $57.3k | | 05/12/2020 |
02/19/2020 | Paratek Pharmaceuticals, Inc. | PRTK | Grant | Common Stock | 135k | $0.00 | $0 | | 02/19/2020 |
10/04/2019 | Paratek Pharmaceuticals, Inc. | PRTK | Grant | Common Stock | 28k | $0.00 | $0 | | 10/04/2019 |
06/05/2019 | Adamas Pharmaceuticals Inc | ADMS | Grant | Stock Option (Right to Buy) | 10k | $4.80 | $48k | | 06/05/2019 |
02/26/2019 | Paratek Pharmaceuticals, Inc. | PRTK | Grant | Common Stock | 120k | $0.00 | $0 | | 02/26/2019 |
02/01/2019 | Paratek Pharmaceuticals, Inc. | PRTK | Grant | Common Stock | 35k | $0.00 | $0 | | 02/01/2019 |
12/12/2018 | Paratek Pharmaceuticals, Inc. | PRTK | Sale | Common Stock | 8.4k | $6.76 | $56.8k | | 12/12/2018 |
10/15/2018 | Paratek Pharmaceuticals, Inc. | PRTK | Sale | Common Stock | 6.3k | $8.96 | $56.4k | | 10/12/2018 |
10/12/2018 | Paratek Pharmaceuticals, Inc. | PRTK | Grant | Common Stock | 14k | $0.00 | $0 | | 10/12/2018 |
07/02/2018 | Paratek Pharmaceuticals, Inc. | PRTK | Sale | Common Stock | 22.5k | $9.97 | $224.3k | | 07/02/2018 |
|